Assessing the distribution of CPC634 in vivo
The biological fate of CriPec®-based candidates can be tracked in vivo by directly combining an imaging agent, such as a fluorescent dye, a NIR label, and/or a PET radiotracer, to the CriPec® candidate.
CPC205 is the radiolabelled derivative of CPC634 i.e. 89Zr-CPC634 that is being used in combination with PET imaging, as a tool to examine drug distribution across the body. It also measures non-invasively its tumour uptake and therefore evaluates the suitability of CPC634 as a targeted treatment option for individual patients. This approach will provide the necessary data to determine if CPC205 has the potential to yield a companion diagnostic for CPC634 nanomedicine.